Publications by authors named "Elena Maria Seminari"
"REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE).
Giuliana Lucia Esposito Federico Fassio Daniela Girardi Erica Picasso Federica Meloni Elena Maria Seminari
Vaccine
October 2024
Background: Infection by SARS-CoV2 has become a challenge, especially for immunocompromised patients who show a weaker humoral response to COVID-19 vaccine. Tixagevimab+cilgavimab (Evusheld) is a combination of human monoclonal antibodies that can be used for pre-exposure prophylaxis to prevent infection or disease by SARS-CoV2.
Objectives: Our study aimed to investigate the effectiveness of Evusheld by comparing an Exposed and an Unexposed group.
Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing in Kidney Transplant Recipients.
Belén Gutiérrez-Gutiérrez Elena Pérez-Nadales Salvador Pérez-Galera Mario Fernández-Ruiz Jordi Carratalà Elena María Seminari
Antimicrob Agents Chemother
October 2021
Article Synopsis
- - The study assessed the effectiveness of ertapenem vs. meropenem in treating bacteremia caused by ESBL-producing bacteria in kidney transplant recipients, using a large cohort from 29 international centers.
- - Among the 201 patients, clinical cure rates at day 14 were similar: 45% for ertapenem and 50.5% for meropenem, indicating that both treatments are comparable in effectiveness.
- - Additionally, over 49% of patients treated with ertapenem showed better outcomes when considering factors like hospital stay and cost, suggesting that ertapenem might offer some advantages over meropenem in this context.